rct
    2018
    High Quality

    AR101 oral immunotherapy for peanut allergy

    PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Burks AW

    Published in New England Journal of Medicine

    Key Findings

    67.2% of AR101-treated participants tolerated 600 mg peanut protein versus 4.0% on placebo, with more adverse events and epinephrine use in the treated group.

    Conclusions

    Oral immunotherapy raises reaction thresholds but does not cure allergy.

    Limitations

    High dropout; efficacy not shown in adults.

    Outcomes Measured

    Allergy Relief

    AR101 immunotherapy raised the tolerated dose of peanut protein compared with placebo.

    Related Health Concerns

    Food Allergies

    Study Details

    Year:2018
    Sample Size:551
    Duration:52 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.